For patients with CNS tumors, any baseline neurologic deficit, including seizures, must be stable for at least one week prior to initiating study treatment
Chemotherapy within 2 weeks of initiating study treatment; there is no maximum allowable number of previous therapies
Patients who received any of the following within the 14 days before initiating study treatment:
Participants who underwent minor surgical procedure within 7 days prior to initiating therapy
Major surgery within 28 days prior to initiating therapy
Progressive disease before initiating study treatment
Central nervous system (CNS) metastasis, unless asymptomatic and stable with no change in CNS disease status for at least two (2) weeks prior to initiating protocol-indicated treatment.\r\n* Anticonvulsant and/or corticosteroid prophylaxis (=< 10 mg/day prednisone or equivalent daily) will be allowed if patient is on a stable or decreasing dose of such treatment for at least 14 days prior to initiating protocol-indicated treatment.
At time of registration and within 4 weeks prior to initiating on-protocol treatment: Platelets >= 100 x 10^9 /L
Platelets >= 75,000 per mm^3 obtained within 14 days prior to initiating study treatment.
Symptomatic hypothyroidism without replacement\r\n* Patients may be rescreened after initiating adequate replacement therapy
Central nervous system (CNS) metastasis, unless asymptomatic or previously treated and stable; and no evidence of CNS progression for at least 30 days prior to initiating protocol-indicated treatment; anticonvulsant and/or corticosteroid therapy will be allowed if patient is on a stable or decreasing dose of such treatment for at least 30 days prior to initiating protocol-indicated treatment
Pregnant and nursing: female patients must have a negative serum pregnancy test within 72 hours prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least 4 weeks following completion of protocol therapy
Any skin-directed therapy within 14 days prior to initiating protocol therapy
Any radiation therapy within 21 days prior to initiating protocol therapy
Systemic estrogens or androgens within 14 days before initiating therapy; vaginal estrogens are allowed if necessary for patient comfort
Systemic estrogens or androgens within 14 days before initiating therapy; vaginal estrogens are allowed if necessary for patient comfort
Major surgery within the four weeks prior to initiating protocol therapy
Anticancer therapy within 2 weeks prior to initiating study treatment
Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study except as detailed above
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatment
The use of anti-convulsants is allowed, as long as the patient is on a stable dose with no seizure activity for at least 2 weeks prior to initiating trial therapy
Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study
Participation in an investigational new drug trial within 28 days prior to initiating treatment on study
Treatment with any investigational drug within 28 days prior to initiating study medications
Patient has had any systemic therapy within 2 weeks prior to initiating study drug.
Patient has participated in a prior investigational study within 3 weeks prior to initiating study drug.
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment; other surgical procedures within 2 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatment
No hormonal therapy is allowed within 1 week of initiating study treatment
Patients must consent to whole blood (2 x 10 mL) submitted prior to initiating chemotherapy
Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.
Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.
Within 72 h of initiating study treatment: Albumin >= 2.5 g/dL
Patients receiving anti-herpes medication within 1 week prior to initiating HF10 treatment.
PHASE I: Prior chemotherapy or radiation administered within 2 weeks from initiating study treatment
Fully recovered from any prior surgery and/or radiation and none within 2 weeks of initiating treatment
Prior systemic therapy within 14 days of initiating protocol treatment
Systemic infection that has not resolved > 2 months prior to initiating lenalidomide
Systemic infection that has not resolved > 2 months prior to initiating lenalidomide treatment in spite of adequate anti-infective therapy
Participation in any clinical study or having taken any investigational therapy for a disease other than CLL within 28 days prior to initiating maintenance therapy.
In the unlikely event that patients are still of childbearing potential, these patients must have a negative serum pregnancy test within 72 hours prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least 4 weeks following completion of protocol therapy
Definitive therapy of the primary uveal melanoma must have been performed within 120 days of initiating protocol therapy
Prior systemic therapy within 14 days of initiating protocol treatment
ELIGIBILITY PRIOR TO INITIATING CT-011:
Corticosteroids discontinued ?7 days of initiating therapy
Progression during the first 3 months of initiating treatment
Initiating focal cranial radiation therapy (photon or proton)
NON-RANDOMIZED OBSERVATIONAL COMPONENT ELIGIBILITY:\r\nUndergoing or initiating active surveillance
Initiating or within 30 days of initiating ADT
Patients who will be initiating therapy with any investigator-initiated mTOR inhibitor based therapy in the Department of Investigational Cancer Therapeutics (phase I program) or initiating radiation therapy to the esophagus
